



## PRESS RELEASE

### **GlaxoSmithKline Renews PER.C6<sup>®</sup> License Agreement with Crucell**

**Leiden, The Netherlands, July 6, 2004** - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL) announced today that GlaxoSmithKline has decided to renew its PER.C6<sup>®</sup> technology license agreement.

Under the terms of the agreement, GlaxoSmithKline has a non-exclusive, worldwide license to use PER.C6<sup>®</sup> technology for research and clinical development of viral-vectored biopharmaceutical products, with an option for a commercial license. Crucell will receive upfront and annual payments. Further financial details were not disclosed.

#### **About Crucell**

Crucell N.V. is a biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria and West Nile virus. The company's development programs include collaborations with Aventis Pasteur for influenza vaccines, the U.S. National Institutes of Health for Ebola and malaria vaccines, and GlaxoSmithKline (GSK), Walter Reed Army Institute of Research and New York University for a malaria vaccine. Crucell's products are based on its innovative PER.C6<sup>®</sup> technology, which offers a safer, more efficient way to produce biopharmaceuticals. The company licenses its PER.C6<sup>®</sup> technology to the biopharmaceutical industry on a mostly non-exclusive basis. Licensees and CMO partners include DSM Biologics, GSK, Centocor/J&J and Merck & Co., Inc. Crucell is headquartered in Leiden, The Netherlands, and currently employs 180 people. Crucell is listed on the Euronext and NASDAQ stock exchanges (ticker symbol CRXL). For more information, please visit [www.crucell.com](http://www.crucell.com).

This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on February 27, 2004, and the section entitled "Risk Factors". The company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP).

#### **For further information please contact:**

##### **Crucell N.V.**

Elizabeth Goodwin  
Director Corporate Communications  
Tel. +31 (0)71 524 8718  
[e.goodwin@crucell.com](mailto:e.goodwin@crucell.com)